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Abstract
Background: Fascin induces membrane protrusions and cell motility. Fascin overexpression was associated with poor 
prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma 
(ESCC). Using a stable knockdown cell line, we revealed the effect of fascin on cell growth, cell adhesion and tumor 
formation.
Methods: We examined whether fascin is a potential target in ESCC using in vitro and in vivo studies utilizing a specific 
siRNA. We established a stable transfectant with downregulated fascin from KYSE170 cell line.
Results: The fascin downregulated cell lines showed a slower growth pattern by 40.3% (p < 0.01) and detachment 
from collagen-coated plates by 53.6% (p < 0.01), compared to mock cells, suggesting that fascin plays a role in cell 
growth by maintaining cell adhesion to the extracellular matrix. In vivo, the tumor size was significantly smaller in the 
tumor with fascin knockdown cells than in mock cells by 95% at 30 days after inoculation.
Conclusions: These findings suggest that fascin overexpression plays a role in tumor growth and progression in ESCC 
and that cell death caused by its downregulation might be induced by cell adhesion loss. This indicates that targeting 
fascin pathway could be a novel therapeutic strategy for the human ESCC.
Background
Esophageal squamous cell carcinoma (ESCC) is one of
the most prevalent cancers worldwide [1,2]. One of the
reasons for its poor prognosis is that ESCC is difficult to
diagnose at an early stage and exhibits local invasion and
lymph node metastasis in its advanced stage, even at ini-
tial diagnosis [3]. The capability of tumor invasion and
metastasis is the result of several sequential steps includ-
ing motile properties of tumor cells to overcome cell-cell
and cell-matrix adhesion and to invade the surrounding
tissue [4-6].
Invasive tumor cells often show morphological
changes, such as membrane pr otrusions as we ll as the
loss of cell-cell adhesion and the loss of junctional com-
munications, which probably result from rearrangements
of the cytoskeletal microfilaments by the action of actin
cross-linking proteins [7-9]. Fascin is a highly conserved
55-kDa actin bundling protein that plays an important
role in the organization of several types of actin-based
structures such as filopodia, lamellipodial ribs, dendrites,
spikes and microvilli [10]. It was originally found in
extracts of unfertilized sea urchin eggs and localized to
microfilament bundles within microvilli cores and within
filopodia on the surface of fertilized sea urchin eggs [11].
Fascin is normally expressed in cells inducing membrane
protrusions and increased cell motility, such as neurons,
glial cells and dendritic cells [12-14] or migrating cells
such as endothelial cells and macrophages [14]. The fas-
cin expression level in epithelial cells is usually low, how-
ever it is often upregulated and overexpressed in
transformed cells and in several types of human neo-
plasm, including breast [15,16], ovary [17], skin [18], pan-
creas and liver [19-21], non-small cell lung carcinomas,
lung carcinoids [22,23], stomach and esophageal
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squamous cell carcinoma [18,24,25]. We have previously
reported that actin bundling protein fascin and its over-
expression was related to poor prognosis, as well as that
its stable knockdown reduces cell motility and invasive-
ness in the ESCC [26]. We have also reported that fascin
immunoreactivity in gastric carcinoma was associated
with lymph node metastasis [27]. In order to determine
whether fascin is a potential gene target, we performed in
vitro and in vivo studies. In the present study, using a sta-
ble knockdown cell line, we elucidated the role of fascin
in cell growth and cell adhesion in vitro and revealed the
effect of fascin knockdown on the tumor growth in the in
vivo tumor formation assay. These results imply a poten-
tially important role of fascin inhibition in the treatment
of ESCC and the prevention of tumor invasion and
metastasis.
Methods
Cell culturing
All human esophageal squamous carcinoma cell lines
KYSE 170 parental (wild) and derivate cells (KYSE
170mock, KYSE 170F3 and KYSE 170F4) were estab-
lished in our laboratory and maintained in RPMI 1640
(Life Technologies, Gaithersburg, MD) and Ham's F12
(Nissui Pharmaceutical, Tokyo, Japan) with 2% fetal
bovine serum (FBS).
Western blot analysis
Whole-cell extract lysate was prepared from 1 × 107 cells
in a sample buffer (2% sodium dodecyl sulfate [SDS], 10%
glycerol, 50 mM Tris-Hcl, pH 6.8) at room temperature.
Cell lysates were sonicated and the protein content was
measured with the Bradford method using BCA Protein
Assay Reagent (Pierce, Rockford, MA), after which the
cell lysates were electrophoresed on a 12% polyacrylam-
ide gel SDS page and transferred to a polyvinylidene dif-
luoride membrane (Immobilon, Milipore, Bedford, MA)
using a semidry transfer blot system (Bio-Rad, Hercules,
CA). The membranes were blocked with TBS (20 mM
Tris, 150 mM NaCl, pH 7.6) containing 1% Tween 20 and
5% skimmed milk for 1 hour. The membranes were incu-
bated overnight at 4°C with anti-human fascin mouse
monoclonal antibody (DAKO, Osaka, Japan; diluted
1:500) or with anti-human β-actin mouse monoclonal
antibody (Sigma Inc., St. Louis, MO; diluted 1:2000) as an
internal control. They were washed and then incubated at
room temperature for 1 hour with anti-mouse IgG-HRP
(Zymed, San Francisco, CA), as a secondary antibody, and
analyzed using ECL plus reagent (Amersham, Bucking-
hamshire, UK).
Purification of total cellular mRNA and Reverse 
Transcription-PCR
Total RNA was extracted from KYSE cell lines by the
TRIzol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer's protocols [28,29]. Reverse transcrip-
tion of total cellular RNA was performed using a First-
Strand cDNA Synthesis Kit (Amersham, Buckingham-
shire, UK). cDNA was subjected to PCR for 25 cycles of
amplification using an Advantage cDNA PCR kit (Becton
Dickinson Biosciences, Palo Alto, CA). Each PCR cycle
consisted of a denaturation step for 1 minute at 94°C and
an annealing step for 1 minute at 60°C. The final exten-
sion step was carried out for 5 minutes at 72°C. The PCR
products were separated on 1.5% agarose gel and visual-
ized by ethidium bromide staining. PCR primers used for
fascin were 5'- AGGCGGCCAACGAGAGGAAC-3' as
the forward primer and 5'-ACGATGATGGGGCGGTT-
GAT-3' as the reverse primer; and for glyceraldehydes-3-
phosphate dehydrogenase (G3PDH), 5'-TGGTATCGTG-
GAAGGACTCATGAC-3' was used as the forward
primer and 5'-ATGCCAGTGAGCTTCCCGTTCAGC-3'
as the corresponding reverse primer. cDNA from HeLa
cells was used as a positive control for each analysis.
Cell growth assay
Cells were plated into 6 cm dishes (2 × 104 cells per dish)
at day 0 and incubated for 24 hours for sufficient cell
growth. Cells were harvested with trypsin/EDTA every
48 hours for five days, and counted with a cell counter
(Coulter Z1, Beckman Coulter, Fullerton, CA). To exam-
ine the effect of the suppression of fascin expression on
cell growth, we compared it with the control culture in
triplicate. Each experiment was repeated three times
independently.
Adhesion assay
Cells were seeded into collagen-coated plates (Becton
Dickinson, MA) without FBS. After 24 hours of incuba-
tion, the adherent and floating cells were counted from
five randomly selected fields. The assay was repeated
three times under the same conditions.
Caspase inhibition
200 μmol/L Z-VAD-FMK (BD Biosciences, San Jose, CA)
was added to the cells after the cells were plated. The
inhibition of cell growth was measured by MTT assay
and cell counting assay. The assay was repeated three
times under the same conditions.
Construction of fascin-small interfering RNA vector and 
transfection
In order to construct a vector for fascin-small interfering
RNA (siRNA), pSilencer2.1-U6 hygro (Ambion, Inc.,
Austin, TX) was digested with BglII and HindIII. A chem-
ically synthesized oligonucleotide encoding a fascin-short
hairpin siRNA that included a loop motif was inserted
downstream of the U6 promoter of the plasmid using a
DNA ligation kit (Takara Bio, Inc., Shiga, Japan), and was
cloned. Sequences of the oligonucleotide targeted to fas-
cin were 5'-GCCUGAAGAAGAAGCAGAU-3' corre-Ortiz et al. Diagnostic Pathology 2010, 5:41
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sponding to positions 116 to 134 within fascin exon 1. An
ESCC cell line KYSE170 was stably transfected with
either the fascin-siRNA expression vector or the negative
control vector (pSilencer2.1-U6 hygro) using FuGene6
reagent (Roche Diagnostics, Basel, Switzerland) [26], and
cell clones were selected against 100 μg/mL hygromycin
(Nacalai Tesque, Kyoto, Japan).
Tumor formation assay in nude mice
Suspensions of 1 × 106 KYSE 170 parental (wild) and deri-
vate cells (KYSE 170mock, KYSE 170F3 and KYSE 170F4)
in PBS (60 μL) were injected subcutaneously into the
right flanks of 5-week-old male BALB/c nu/nu mice
(Japan SLC, Shizuoka, Japan) at day 0. The inoculation
was conducted in five mice per group, and tumor growth
was estimated from the average volume of tumors by the
formula: 1/2 × L2 × W (where L is the length of the tumor
and W is the width of the tumor). At 30 days after injec-
tion, all mice were sacrificed and the subcutaneous
tumors were resected and fixed in 10% formaldehyde/
PBS. Tumors were then embedded in paraffin and stained
with H&E and fascin. All animal experiments were per-
formed in accordance with institutional guidelines.
Immunohistochemical staining
Resected tumors from the in vivo experiments were fixed
in 10% formaldehyde solution, embedded in paraffin, cut
in 4 μm thick sections, and mounted on aminopropyltri-
ethoxylane-coated glass slides. Immunohistochemical
staining was carried out using an Envision Kit (Dako
Cytomation, Glostrup, Denmark). Tissue sections were
incubated overnight at 4°C with anti-human fascin
monoclonal antibody clone 55kDa (DAKO, Osaka, Japan;
1:50 dilution) and then incubated with biotinylated anti-
mouse IgG for 30 minutes at room temperature. Tissue
sections were then stained with 3,3' diaminobenzidine
liquid system (Dako Cymation, Glostrup, Denmark),
counterstained with Mayer's haematoxilyn, dehydrated
and mounted. We performed the same protocol using
goat anti-human caspase 3 polyclonal antibody (Santa
Cruz Biotechnology, CA, USA; dilution 1:500). As a nega-
tive control, the primary antibody was replaced with nor-
mal mouse IgG, and a further control was carried out
without the primary antibody.
TUNEL assay
The DeadEnd Colorimetric TUNEL system kit was used
for the TUNEL assay. The paraffin-embedded tissues
were fixed in 4% formaldehyde with PBS for 15 minutes,
permeabilized with 20 μg/ml proteinase K for 15 minutes
and subsequently incubated at 37°C for 60 minutes with
the rTdT reaction mix on the slide. Streptavidin HRP
solution 1:500 in PBS was added and incubated for 30
minutes. DAB solution was then added for 5 minutes.
Then the apoptotic cells were counted in five different
fields at 40 ×, obtaining the average and standard devia-
tion (SD).
Statistical analysis
The statistical analysis was performed using the software
StatView 4.5 (Abacus Concept, Berkley, CA). A p-value of
< 0.05 indicated statistical significance.
Results
Downregulation of fascin expression by siRNA in ESCC cell 
lines
The expression of fascin was reduced by 74.8% in the sta-
ble subclones 170F1, 89.1% in 170F2, 93% in 170F3 and
97.7% in 170F4. The transfection for the nonspecific
siRNA vector (170 mock) did not affect the expression of
fascin. HeLa cells were used as a positive control for fas-
cin (Figure 1A). Semiquantitative reverse transcription-
PCR was performed, obtaining similar results to western
blot analysis (Figure 1B).
siRNA against fascin decreased cell growth of ESCC in vitro
We hypothesized that knockdown of fascin might affect
cell growth. In order to verify this hypothesis, we investi-
gated the effect of fascin knockdown on proliferation in
one ESCC cell line (KYSE 170). With the suppression of
fascin, the cell growth was inhibited by 40.3% in KYSE
Figure 1 Expression of fascin in parental KYSE cells and stable 
transfectant with siRNA. (A) Western blot analysis in parental KYSE 
170 cells and stable transfectant with siRNA. The HeLa cell line was in-
cluded as a positive control for fascin expression. (B) Semiquantitative 
reverse transcription-PCR analysis for fascin expression in parental 
KYSE 170 cells and stable transfectant with siRNA. The HeLa cell line 
was included as a positive control in the same analysis.
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70F4 at the day 5, as compared to the empty vector siRNA
transfected cell line (KYSE 170 mock) (p < 0.01) (Figure
2).
siRNA against fascin decreased cell adhesion of ESCC in 
vitro
In the cell adhesion in vitro experiment, the differences
between KYSE 170 mock and fascin knockdown cells
were not observed until 6 hours after seeding. The KYSE
170 mock cells attached well after 6 hours, whereas the
fascin knockdown cells (KYSE 170F4) did not attach
properly and an increasing number of cells was floating.
After 24 hours of seeding, the number of adherent living
cells was significantly lower in the KYSE 170F4 group
than in the KYSE 170 mock group (Figure 3A); in con-
trast, the number of floating cells increased (Figure 3B).
As a result, the total number of cells decreased in the fas-
cin knockdown group. These results suggest that fascin
knockdown induces the loss of cell adhesion to the matrix
and might result in the inhibition of cell growth in ESCC
cells.
Adhesion assay using a general caspase inhibitor (Z-VAD-
FMK)
The general caspase inhibitor (Z-VAD-FMK) did not
affect the inhibition of attachment induced by fascin
knockdown (Figures 3C and 3D). The difference in cell
count at 72 hours between the fascin knockdown cell line
and the mock cell line remained the same, both using the
general caspase inhibitor and without (mean 40.1% both).
These results provide convincing evidence that detach-
ment may be caused by fascin knockdown.
Effect of fascin on pFAK and Integrin α2 expression in vitro
Using the in vitro model and western blot analysis, we
observed a decreasing expression of the two proteins
involved in attachment and cell cycle signaling pFAK and
Integrin α2 in all the studied clones, with the highest
expression in KYSE 170wild and mock, and the lowest
expression in KYSE 170F4 cells (Figure 4). These results
suggest that the occurrence of interactions between fas-
cin and other proteins or membrane proteins may occur.
Effect of fascin knockdown on tumor formation in vivo
In order to investigate the possible effect of fascin-siRNA
on tumor formation in vivo, we performed a subcutane-
ous tumor formation assay in nude mice (Figure 5A). We
evaluated tumor volume and weight at 30 days after inoc-
ulation. The tumor formations caused by fascin-siRNA
transfected cells (KYSE 170F3 and KYSE 170F4) were evi-
dently smaller than those formed by KYSE 170wild and
KYSE 170 mock (Figure 5B). The average tumor volume
was significantly lower in KYSE 170F3 and KYSE 170F4
by 91% and 95%, respectively, compared to KYSE 170
mock (p < 0,0001 and p < 0,0001, respectively). The aver-
age tumor weight was also inhibited in KYSE 170F3 and
KYSE 170F4 by 87% and 90%, respectively (p < 0,0004 and
p < 0,0003, respectively). Finally, all tumors were stained
with H&E and fascin, and fascin protein expression was
reduced to a minimum in tumors of inoculated mice with
fascin-siRNA transfected cells, although not in tumors of
empty vector transfected cells (KYSE 170 mock) (Figure
6).
siRNA for fascin induced apoptosis of ESCC in vivo
The analysis of tumoral apoptosis was conducted by
TUNEL assay (Figure 7A) and immunohistochemistry for
caspase 3 (Figure 7B) where the number of apoptotic cells
was higher in the fascin downregulated tumor than in the
KYSE 170 mock tumor. For the TUNEL assay, the average
of apoptotic cells in the fascin knockdown tumor was 15
± 3.6 cells per high power field and for the KYSE 170
mock tumor it was 2 ± 0.83 cells per high power field.
Discussion
Although there are many reports demonstrating the
involvement of fascin in carcinogenesis, its biological role
and the relationship with the different oncogenic path-
ways in tumorigenesis is still unclear. In this study, we
s h o w e d  t h a t  f a s c i n  k n o c k d o w n  s t r o n g l y  i n h i b i t s  c e l l
growth and cell adhesion abilities of the ESCC cell line
KYSE 170 in vitro and in vivo. This is most likely due to
focal detachment to the matrix of tumoral cells, suggest-
ing that the occurrence of interactions between fascin
and other proteins or membrane proteins may occur. The
ability of tumor cells to migrate might be connected to
Figure 2 Vector based siRNA for fascin knockdown in the ESCC 
cell line. In vitro growth assay in KYSE 170 cells and stable transfectant 
cells with an empty vector (KYSE 170 mock) or fascin-siRNA vector 
(KYSE 170F3 and KYSE 170F4). The cells were counted every two days 
and the experiment was performed three times.
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their tumorigenicity, and fascin might participate in path-
ways regulating migration, cell growth and detachment-
induced apoptosis (anoikis) [25,30-32].
The changes involved in cell proliferation might be cru-
cial in regulating tumor growth and progression. In our
experimental design, in vitro studies showed that the
inhibition of cell growth by fascin knockdown was time
dependent, visible evidence in the cell number was not
observed until 24 hours after seeding. Furthermore, the
caspase general inhibitor did not affect the inhibition of
growth caused by fascin knockdown. These results sug-
gest that the inhibition of cell adhesion caused by fascin
knockdown results in the inhibition of cell growth. Fascin
knockdown cells strongly inhibited tumor growth in vivo.
Although this inhibition might be the result of several
factors, our data for TUNEL assay and caspase 3 immu-
nohistochemical staining for the in vivo experiment con-
firmed that apoptosis was higher in the fascin
knockdown cells. The mechanism by which apoptosis is
induced by fascin knockdown is unclear. This data sup-
Figure 3 Adhesion assay of  stable transfectant cells with an empty vector (KYSE 170 mock) compared to a siRNA vector against fascin 
(KYSE 170F4). (A) Total number of cells, number of floating dead cells and number of adherent living cells for stable transfectant cells with an empty 
vector (KYSE 170 mock) as compared to a siRNA vector against fascin (KYSE 170F4). Left, the total number of cells (× 104 cells/dish). Middle, the number 
of floating dead cells (× 103 cells/ml). Right, the number of adherent living cells (× 103 cells/ml). (B) Photographs of ESCC 24 hours after seeding. (a') 
Adherent stable transfectant cells with an empty vector (KYSE 170 mock). (b') Floating stable transfectant cells with an empty vector (KYSE 170 mock). 
(c') Adherent stable transfectant cells with a siRNA vector against fascin (KYSE 170F4). (d') Floating stable transfectant cells with a siRNA vector against 
fascin (KYSE 170F4). (C) Effect of fascin knockdown and the effect of caspase dependency in cell growth. The cells were treated with 200 μmol/L of 
the general caspase inhibitor Z-VAD-FMK (+). (D) Control, without the general caspase inhibitor Z-VAD-FMK (-).
A C
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D
Figure 4 Western blot analysis for the expression of fascin, pFAK 
and integrin α2 proteins in parental KYSE170 cells and the stable 
transfectant with siRNA.
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Figure 5 The effect of fascin knockdown on tumor formation model. (A) Tumor subcutaneous implantation 30 days after inoculation. (a') Fascin 
knockdown cells (KYSE 170F4) were injected subcutaneously in the right flank. (b') The KYSE 170 mock cells were injected in the right flank. (B) Tumor 
growth curves of mice injected with KYSE 170 wild type cells, empty vector-transfected cells (KYSE 170 mock) and fascin siRNA-transfected cells (KYSE 
170F3 and KYSE 170F4).
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ports our suggestion that detachment might be a cause,
rather than a result of apoptosis, resulting in the inhibi-
tion of cell growth. However, the results on the in vitro
growth assay were rather different compared with the in
vivo growth assay, where the inhibition of the cell growth
in vitro was lower than in the in vivo study. There are sev-
eral mechanisms involved in the xenograft model, and the
tumor growth is strongly associated with the tumor
microenvironment, including the extracellular matrix
and cellular components such as fibroblasts, endothelial
cells, smooth muscle cells and inflammatory cells
(stromal cells) [33,34]. Other reports have demonstrated
the mechanism by which fibroblasts promote tumor cells
growth in vivo compared with the in vitro model [35,36].
Cell-matrix and cell-cell adhesive interactions play cru-
cial roles in the organization and stability of normal epi-
thelial cells. The conversion of normal cells into
malignant cells induces changes in the molecules
involved in the adhesion system, which enable a switch to
migratory-invasive phenotype in tumor metastasis [37].
These changes are present in ESCC cells, allowing the
cells to migrate and invade generating metastasis. The
involvement and interaction between fascin and all
changes in the membrane are unclear. Malignant tumor
cells display a varying degree of resistance to detachment,
generating cell-extracellular matrix interactions that are
related with the adhesion complex, and this property
contributes to tumorigenesis and metastasis [38]. FAK
(Focal Adhesine Kynase) is a 125 kDa nonreceptor
tyrosine kynase, which regulates cell survival, invasion,
migration and cell cycle [39], and its overexpression in
human malignant cells has been reported [40-43]. We
observed the inhibition of the pFAK by western blot anal-
ysis in the KYSE 170 F4 cells. FAK interacts with MAPK
cascade regulating cell cycle [44-47]. Furthermore, Integ-
rin α2 is a collagen counter receptor and its knockdown
leads to the loss of cell-extracellular matrix adhesion [47].
We observed a considerably low immunoreactivity for
integrin α2 through western blot analysis by using the in
vitro model. The cell-cellular matrix adhesion is required
for the continuous activation of the FAK pathway. There-
fore, the mechanism of the inhibition of cell growth by
fascin knockdown is likely to be partially due to the
decrease in the expression of integrin α2. Further
research is necessary in order to understand this mecha-
nism.
Cell adhesion and motility functions must be regulated
in a coordinated fashion during tumorigenicity. Fascin
interacts strongly with β-catenin via an extended region
that is known to be necessary for interaction between β-
catenin and E-cadherin [22,30,48,49], indicating that fas-
cin and the cytoplasmic domain of E-cadherin compete
Figure 6 Immunohistochemical expression of fascin in subcutaneous tumors. (a) Fascin immunohistochemical staining of subcutaneous tu-
mors 30 days after inoculation of fascin siRNA transfected cells (KYSE 170F3).. (b) H&E staining of subcutaneous tumors 30 days after inoculation of 
fascin siRNA transfected cells (KYSE 170F3). (c) Fascin immunohistochemical staining of subcutaneous tumors 30 days after inoculation of fascin siRNA 
transfected cells (KYSE 170F4). (d) H&E staining of subcutaneous tumors 30 days after inoculation of fascin siRNA transfected cells (KYSE 170F4). (e) 
Fascin immunohistochemical staining of subcutaneous tumors 30 days after inoculation of the empty vector-transfected cells (KYSE 170 mock). (f) 
H&E staining of subcutaneous tumors 30 days after inoculation of the empty vector-transfected cells (KYSE 170 mock). The assay was performed using 
five mice per group.
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for the association with β-catenin. From this perspective,
it is still unclear which molecular mechanism underlies
the role of fascin in the cadherin-catenin complex system
in the regulation of cell proliferation, invasion and cell
signaling during tumor progression. We found that β-
catenin expression was higher in the membrane of KYSE
170F4 cells in both in vitro and in vivo models, as com-
pared to fascin mock cells, where the expression of β-
catenin was located mainly in the cytoplasm and nuclei
(Additional files 1 and 2).
Conclusions
In conclusion, we have identified a potentially important
role of fascin in ESCC, where the knockdown of fascin in
an ESCC cell line using a siRNA vector induced several
effects on cell adhesion, cell growth and the subsequent
survival of the ESCC cell line and decreased tumor for-
mation in vivo. These findings indicate that fascin may
play a role in the prevention of further tumor growth and
survival. However, further experiments are necessary in
order to determine whether fascin contributes to other
pathways involved in transformation, cell growth, sur-
vival and metastasis.
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